Lord, Abbett & Co
AXDX

Lord, Abbett & Co’s Accelerate Diagnostics AXDX Stock Holding History

Lord, Abbett & Co’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-5,700
Closed -$1.3M – 845
2018
Q1 		$1.3M Buy
+5,700
New +$1.5M ﹤0.01% 812

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
NCGI
Next Century Growth Investors Plymouth, Minnesota $1.38B AUM 102.34% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Lord, Abbett & Co's AXDX Position: Q2 2018 in Review

Lord, Abbett & Co sold out of Accelerate Diagnostics (AXDX) in Q2 2018, closing a stake of 5,700 shares — an estimated $1.3M sold.

Lord, Abbett & Co first reported a position in AXDX in Q1 2018 and held it in 1 quarter. The position peaked at $1.3M in Q1 2018. 117 funds tracked by Wall St. Rank hold AXDX as of Q2 2018.

  • Lord, Abbett & Co reported no remaining Accelerate Diagnostics position as of Q2 2018 after selling out during the quarter.
  • Lord, Abbett & Co sold 5,700 Accelerate Diagnostics shares in Q2 2018, an estimated $1.3M.
  • Lord, Abbett & Co first reported a position in Accelerate Diagnostics in Q1 2018 and held it in 1 quarter.
  • Lord, Abbett & Co's Accelerate Diagnostics position peaked at $1.3M in Q1 2018.
  • 117 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2018.

Based on Lord, Abbett & Co's 13F filing for Q2 2018, filed 14 Aug 2018.